文献速递神经肿瘤

孕激素受体表达与预测新发非典型脑膜瘤全切除后辅助放疗获益

Progesterone receptor expression and prediction of benefits of adjuvant radiotherapy in de novo atypical meningiomas after gross-total resection.
PubMed 文献 · J Neurosurg · 2022-11-04

研究纳入2010至2018年231例新发非典型脑膜瘤全切除(Simpson I-III级)患者,138例(59.74%)接受辅助放疗,孕激素受体(PR)阳性157例(67.97%)。中位随访76.25个月,辅助放疗是疾病特异性生存的独立预后因素(p=0.025),但对无进展生存无独立预测价值(p=0.068);PR阴性亚组从辅助放疗中获益(p=0.002),PR阳性亚组未见获益(p=0.86)。

要点

  • 辅助放疗是新发非典型脑膜瘤全切除后疾病特异性生存的独立预后因素(p=0.025)。
  • 辅助放疗对无进展生存的多因素分析未达统计学显著(p=0.068)。
  • PR阴性亚组从辅助放疗中获益(p=0.002),PR阳性亚组未见获益(p=0.86)。

核心结论

  • 辅助放疗是新发非典型脑膜瘤全切除患者疾病特异性生存的独立预后因素(p=0.025),但对无进展生存不是(p=0.068)。
  • PR阴性表达是新发非典型脑膜瘤全切除后无进展生存的放疗敏感性生物标志物。

研究设计与样本

  • 纳入2010至2018年连续231例经病理诊断为新发非典型脑膜瘤并接受全切除(Simpson I-III级)的患者。
  • 收集并分析临床病理与预后信息,采用单因素和多因素Cox分析评估预后预测因素并比较放疗反应。
  • 采用倾向性评分匹配(PSM)平衡亚组混杂偏倚。

主要发现

  • 138例(59.74%)接受辅助放疗,PR表达阳性157例(67.97%)。
  • 平均随访76.25个月期间,65例(28.14%)复发,38例(16.45%)死于肿瘤进展。
  • 疾病特异性生存:辅助放疗单因素分析p=0.003、多因素分析p=0.025。
  • 无进展生存:辅助放疗单因素分析p=0.013,多因素分析p=0.068。
  • PR阳性(p=0.019)、年龄53.5岁或以下(p=0.012)、Ki-67 7.5%或以下(p=0.025)为无进展生存更好的独立预后预测因素。

关键数值与推荐

  • PR阴性亚组中观察到辅助放疗的获益(p=0.002),PR阳性亚组中未观察到(p=0.86)。
  • 异质性分析显示PR阴性亚组较PR阳性亚组对辅助放疗更敏感(p=0.036)。
  • 辅助放疗与更好无进展生存的关联在年轻患者(≤53.5岁,p=0.14)、年长患者(>53.5岁,p=0.085)、Ki-67≤7.5%者(p=0.068)及Ki-67>7.5%者(p=0.13)中均未观察到。
  • 倾向性评分匹配后,PR阴性与PR阳性亚组中辅助放疗的相反效应仍然成立。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Benefits of adjuvant radiotherapy (ART) after gross-total resection (GTR) of de novo atypical meningiomas (AMs) are controversial, and factors predictive of radiotherapy benefits in patients with de novo AMs after GTR are unknown. The authors aimed to evaluate the benefits of ART and explore potential factors sensitizing AMs to ART. METHODS: A total of 231 consecutive patients who were pathologically diagnosed with de novo AMs and treated with GTR (Simpson class I-III resections) from 2010 to 2018 were enrolled in the study. Clinicopathological and prognostic information was collected and analyzed. Univariate and multivariate Cox analyses were used to evaluate prognostic predictors and compare the response to radiotherapy. Propensity score matching (PSM) was used to balance the confounding bias in subgroups. RESULTS: A total of 138 patients (59.74%) received ART. Progesterone receptor (PR) expression was positive in 157 patients (67.97%). During the mean follow-up period of 76.25 months, 65 patients (28.14%) experienced recurrence and 38 (16.45%) died of tumor progression. For disease-specific survival (DSS), ART was a better prognostic factor via univariate (p = 0.003) and multivariate (p = 0.025) analyses. For progression-free survival (PFS), univariate Cox analysis showed that ART improved PFS (p = 0.013), but multivariate analysis did not (p = 0.068). Positive PR expression (p = 0.019), age 53.5 years or younger (p = 0.012), and Ki-67 7.5% or lower (p = 0.025) were independent prognostic predictors for better PFS. In the subcohort analysis, the beneficial impact of ART was observed in the PR-negative cohort (p = 0.002) but not in the PR-positive cohort (p = 0.86). The heterogeneity analysis demonstrated that the PR-negative cohort was more sensitive to ART than the PR-positive cohort (p = 0.036). ART was not found to be associated with better PFS in younger patients (≤ 53.5 years, p = 0.14), older patients (> 53.5 years, p = 0.085), those with a Ki-67 index ≤ 7.5% (p = 0.068), or those with a Ki-67 > 7.5% (p = 0.13). The contrasting effects of ART in the PR-negative versus PR-positive cohorts remained true even after PSM, confirming that PR-negative, but not PR-positive, de novo AMs benefited from ART after GTR. CONCLUSIONS: ART was an independent prognostic factor for DSS of patients with de novo AMs treated with GTR (p = 0.025), but not for PFS (p = 0.068). Negative PR expression was a radiosensitive biomarker on PFS for de novo AM patients after GTR.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ren L, Cheng H, Chen J, et al. Progesterone receptor expression and prediction of benefits of adjuvant radiotherapy in de novo atypical meningiomas after gross-total resection. J Neurosurg. 2022. PMID: 36334291. doi:10.3171/2022.9.JNS221530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。